逍遥散联合拉米夫定治疗慢性乙型肝炎39例预后分析

Effect of Xiaoyao Powder Combined with Lamivudine on Prognosis of 39 Patients with Chronic Hepatitis B

目的探讨逍遥散联合核苷类抗病毒药物治疗的慢性乙型肝炎患者的生存质量及预后。方法选取2010年2月至2011年2月在医院确诊为乙型肝炎并接受住院治疗的患者78例,根据治疗方法的不同分为观察组和对照组,各39例。两组患者住院期间均给予相同的综合护理,观察组患者接受逍遥散联合核苷类抗病毒药物拉米夫定治疗,对照组患者仅接受拉米夫定治疗。结果治疗1年及2年后观察组健康调查简表(SF-36量表)、慢性肝病量表(CLDQ)评分改善均较明显(P<0.05);治疗1年后,观察组除SF-36量表的生理职能、情感职能2个维度外,其他6个维度评分均明显优于对照组(P<0.05),且观察组CLDQ量表各类评分均明显优于对照组(P<0.05);治疗2年后,观察组SF-36量表的8个维度得分均显著优于对照组(P<0.05),CLDQ量表除活动、系统症状2个类别外,其他4个类别评分均高于对照组(P<0.05);6年内观察组癌变率为17.95%,明显低于对照组的38.46%。结论逍遥散联合核苷类抗病毒药物拉米夫定治疗慢性乙型肝炎,患者生存质量明显改善,且可有效降低肝癌发生率。

Objective To investigate the clinical effect of Xiaoyao Powder combined with nucleoside antiviral drugs for treating patients with chronic hepatitis B and its effect on the quality of life and related prognostic outcomes.Methods Totally 78 patients with chronic hepatitis B admitted to our hospital from February 2010 to February 2011 were selected and divided into the observation group and the control group according to the different treatment methods,39 cases in each group.The two groups were given the same comprehensive nursing during hospitalization.The observation group received Xiaoyao Powder combined with nucleoside antiviral drugs(lamivudine),while the control group only received lamivudine.Results After 1 year and 2 years of treatment,the scores of SF-36 and CLDQ in the observation group improved significantly(P<0.05).1 year after treatment,In addition to the 2 dimensions of physiological function and emotional function,the scores of the other 6 dimensions in the SF-36 scale of the observation group were significantly better than those of the control group(P<0.05),and the scores of CLDQ were better than the control group(P<0.05).2 years after treatment,the scores of SF-36 in all dimensions of the observation group were better than those of the control group(P<0.05),in addition to 2 categories of activity(AC)and systemic symptoms(SS),the scores of the other 4 categories in the CLDQ scale of the observation group were higher than those of the control group(P<0.05).In 6 years,the rate of carcinogenesis in the observation group was 17.95%,which was significantly lower than 38.46%in the control group(P<0.05).Conclusion Xiaoyao Powder combined with nucleoside antiviral drugs(lamivudine)for treating patients with chronic hepatitis B can significantly improve the patients’quality of life and effectively reduce the occurrence rate of liver cancer.